Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib, Durvalumab, and Radiation Therapy in Locally Advanced Unresectable Pancreatic Cancer
NCT05411094Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of olaparib and durvalumab in pancreatic cancer (PC), sponsored by National Cancer Institute. Primary endpoint: Dose-limiting toxicities up to 6 weeks. Started May 2023; status: active, not recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05411094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411094.